Patents by Inventor Philipp CLAAR

Philipp CLAAR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FACTOR IX VARIANT POLYPEPTIDES FOR ADMINISTRATION TO SOFT TISSUE
    Publication number: 20260130974
    Abstract: This invention relates to Factor IX variant polypeptides for administration to soft tissues.
    Type: Application
    Filed: October 6, 2023
    Publication date: May 14, 2026
    Inventors: Steffi Knoll MACHADO, Padmapriya PONNUSWAMY, Sabine PESTEL, Philipp CLAAR
  • Factor IX variants and uses thereof in therapy
    Patent number: 12577552
    Abstract: This invention provides Factor IX variants, molecules comprising the variants, nucleic acids encoding the variants, compositions comprising the variants or the nucleic acids encoding the variants, and their use in methods for the modulation of hemostasis, for example in the prophylaxis or treatment of hemophilia B. The Factor IX variants have improved biological properties relative to other Factor IX variants and/or relative to wild-type Factor IX.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: March 17, 2026
    Assignee: CSL Innovation Pty Ltd
    Inventors: Philipp Claar, Thomas Weimer, Walid Azar, Holger Lind, Marco Hofmann
  • FACTOR IX SUBCUTANEOUS ADMINISTRATION WITH ENHANCED SAFETY
    Publication number: 20240293516
    Abstract: This invention relates to Factor IX compositions and their uses in therapy by subcutaneous administration. In particular, high-activity Factor IX compositions for subcutaneous administration comprising advantageous Factor IX protein concentrations are provided, which minimize the risk of local tolerability issues, thereby providing enhanced safety.
    Type: Application
    Filed: June 28, 2022
    Publication date: September 5, 2024
    Inventors: Sabine PESTEL, Philipp CLAAR
  • FACTOR IX VARIANTS AND USES THEREOF IN THERAPY
    Publication number: 20220154161
    Abstract: This invention provides Factor IX variants, molecules comprising the variants, nucleic acids encoding the variants, compositions comprising the variants or the nucleic acids encoding the variants, and their use in methods for the modulation of hemostasis, for example in the prophylaxis or treatment of hemophilia B. The Factor IX variants have improved biological properties relative to other Factor IX variants and/or relative to wild-type Factor IX.
    Type: Application
    Filed: March 18, 2020
    Publication date: May 19, 2022
    Inventors: Philipp CLAAR, Thomas WEIMER, Walid AZAR, Holger LIND, Marco HOFMANN